Pictor® Celebrates a Year of Progress with U.S. Headquarters Success

Pictor Holdings Inc., a global leader in targeted proteomics, has reached an impressive milestone as it commemorates one year since the establishment of its U.S. headquarters in Carlsbad, California. With the rapid evolution of laboratory demands for more efficient and effective testing methods, Pictor has positioned itself at the forefront of innovation in multi-analyte testing. Over the past year, the company has significantly expanded its commercial footprint, reporting numerous achievements that underline its commitment to improving health diagnostics across human and animal health sectors.

A Year of Achievements and Expansion

In just twelve months, Pictor has successfully enriched its product line to include seven commercial products, secured four strategic partnerships, and upgraded its Carlsbad facility with a state-of-the-art laboratory equipped to enhance research and development capabilities. Among notable collaborations, Pictor partnered with a prominent global pharmaceutical company and forged important ties with Disease Research Limited in New Zealand to facilitate the launch of its PictVet® MAP assay in the dairy and beef industries.

The establishment of a tailored laboratory has opened doors for broader research opportunities and operational improvements. Pictor's team is not only experienced but also newly strengthened by the addition of key leadership figures. Dr. Terry Kelly, recently appointed as Chief Operating Officer, brings over two decades of expertise in assay development, while Tim Shannon, the new Chief Financial Officer, enhances the financial strategic approach of the company. Their joint expertise is expected to guide Pictor in scaling operations and navigating the burgeoning market for targeted proteomics.

Meeting Market Demands

Pictor's innovative targeted proteomic platform is engineered to analyze multiple protein targets within a single sample in under two hours, all while maintaining affordability. The platform operates with the proprietary Pictorial© software and utilizes the advanced AI-driven PictImager® imaging system to democratize access to proteomics. This ease of use combined with cost-effectiveness makes Pictor’s solutions appealing to laboratories looking to enhance their testing capabilities efficiently.

CEO Jamie Platt, PhD, reflects on the past year: “We joined an innovative biotech community eager for targeted proteomic workflows. The consistent demand for our solutions and the partnerships we've formed validate our approach. Our second year is poised for expansion—more partnerships, broadened market reach, and a greater emphasis on innovative science.” The company is resolute that its first-year achievements lay a solid foundation for future growth in a market craving advanced scientific solutions.

Future Directions and Growth Strategies

Looking forward, Pictor aims for a substantial U.S. Series A funding round of up to $30 million. This capital influx will facilitate scaling laboratory capabilities, enhancing assay development processes, broadening the team, and expanding the company's intellectual property portfolio. With the growing global demand for effective diagnostics, Pictor plans to accelerate its entrance into licensing agreements with a variety of partners, aiming for completion within the next 12 to 18 months.

Additionally, as the adoption of targeted proteomic workflows continues to proliferate through various healthcare and veterinary sectors, Pictor is set to deepen existing collaborations while establishing new ones globally. The company invites partners and stakeholders to explore the benefits of integrating Pictor's solutions into their operations.

About Pictor Holdings Inc.

Founded in New Zealand and now headquartered in Carlsbad, California, Pictor Holdings Inc. is dedicated to producing multi-analyte proteomic assays tailored for both human and animal health research environments. Pictor enables laboratories and biopharmaceutical partners to perform more analyses, faster and at reduced costs. The company's robust intellectual property portfolio reflects its commitment to innovation, including 16 patents, five pending, and seven registered trademarks. For more details, visit www.pictorproteomics.com.